Contact Activation Pathway Function Blocking Antibody AB023

• Shall target specific blood clotting factors without increasing the risk of bleeding
  • Shall bind to the "apple 2" domain of FXI, inhibiting its activation by activated factor XII (FXIIa) in the "contact pathway" which drives clot formation in artificial surfaces
  • Shall be designed for use in Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-related thrombosis
• Shall preserve natural clotting (hemostasis)
  • Shall not block the activation of FXI by thrombin 
  • Shall not block the conversion of Factor IX by activated Factor XI (FXIa), which allows it to preserve the necessary hemostatic function of FXI activation by thrombin required for normal wound healing
• Shall provide a maximum of 0.5g of AB023 each year
• Shall conduct pharmacokinetics (PK) testing to determine its concentration over time and pharmacodynamics (PD) analyses on the biochemical, physiological, and molecular effects of the drug
  • Shall cause a dose-dependent prolongation of the activated partial thromboplastin time (aPTT), measures how long it takes for blood to clot
  • Shall not affect Prothrombin Time (PT), a blood test that measures how many seconds it takes for blood to clot
  • Shall be effective at preventing platelet-rich thrombus growth and fibrin accumulation in vascular thrombosis models
• Shall be validated by using clotting assays to ensure stability, dose and potency

The Government is not obligated to, nor will it, pay for or reimburse any costs associated with responding to this RFI. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No subcontracting opportunity is anticipated. The North American Classification System (NAICS) code for this acquisition is 541714 – Research and Development in Biotechnology (except Nanobiotechnology); (Small Business Size Standard 1,000 employees).

Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered in the System for Award Management (SAM) at www.sam.gov and complete online representations and certification in SAM.

All interested parties shall submit information by email to: [email protected], and [email protected] to be received no later than 18 June 2026, at 10:00ET.